Untitled 1 1024x538 1 captis executive search management consulting leadership board services

Rapid Unit Sales of Medical Masks to Account for Incremental Revenues in the Global Market Through the COVID-19 Crisis Period

Untitled 1 1024x538 1 captis executive search management consulting leadership board services

Medical facilities are highly dependent on the use of medical masks during surgeries. The availability of different versions of mask for different applications across different end-users, such as ambulatory surgical centre’s, hospitals, dental settings, etc., are expected to fuel the growth of the medical mask market throughout the forecast period.

The surgeries performed globally are also boosting the demand for anaesthesia masks and laryngeal masks, which are expected to contribute to the growth of the medical mask market during the forecast period.  The COVID-19 pandemic is also enhancing the uptake of medical masks for personal protection of healthcare workers. The global medical mask market was estimated at US$ 9517.9 Mn in 2019, and is projected to witness moderate growth during the forecast period (2020 – 2030).

For detailed insights on enhancing your product footprint, request a sample here- https://www.factmr.com/connectus/sample?flag=S&rep_id=4732

Key Takeaways of Medical Mask Market Study

  • A large number of companies manufacturing N95 respirators masks have contributed significantly to the market share in terms of revenue in the medical mask market.
  • North America and Europe collectively hold over 50% of the medical mask market share owing to new product launches in these regions.
  • In terms of end users, hospitals are expected to dominate the medical mask market during the forecast period.
  • The medical mask market is highly fragmented. Some of the prominent manufacturers include GE Healthcare (US), 3M (US), Medline Industries, Inc. (US) and few others.

“Growth in the number of surgeries performed globally as well as an increase in the number of infectious diseases and pollution will also fuel the growth of medical mask market,” says a Fact.MR analyst.    

Medical Masks to Witness Rampant Adoption with Rising Prevalence of COVID-19

COVID-19 is purported to be a major public health burden worldwide. The growing prevalence of COVID-19 is creating social, economic and clinical challenges. Medical masks are increasingly being used in healthcare settings to prevent disease transmission and protect healthcare workers from getting infected. With tremendous burden on healthcare staff to take care of sick patients, hospitals are mandating the use of medical masks to ward off infections and reduce fatalities and infection rates among the medical staff.

To get all-in insights on the regional landscape of the Medical Mask market, buy now- https://www.factmr.com/checkout/4732/S

Looking for More Information?

The research study on medical mask market by Fact.MR incorporates an unbiased assessment of key demand-driving factors and trends, which have shaped the landscape of medical mask over 2015 – 2019 and includes a detailed assessment of key parameters that are anticipated to exert influence over 2020 – 2030. Market statistics have been presented on the basis of product type (surgical mask, N95 respirators, face mask, full-face mask, laryngeal masks, and anesthesia masks), application (respiratory safety, infections disease, allergies and surgeries) and end user (hospitals, academic & research institutes, diagnostic laboratories, individual) across seven prominent regions.

Explore Fact.MR’s Coverage on the Healthcare Domain

Protective Face Mask Market: A recent study by Fact.MR on the Protective Face Mask Market offers a 10-year forecast analysis for the period 2020 to 2030. The study analyses key trends that are currently influencing the growth of the market. This report covers key dynamics, including drivers, restraints, and opportunities for leading market players along with key stakeholders and emerging players.

High Concentration Respiratory Masks Market: Fact.MR’s extensive coverage on the High Concentration Respiratory Masks Market offers in-depth insights into the prominent growth dynamics that are likely to aid the expansion of growth prospects in the near future. Data has been presented in the form of key segments across prominent geographies, along with important information concerning key manufacturers operating within the industry.

Anti-Pollution Mask Market: The Anti-Pollution Mask Market study published by Fact.MR offers an unbiased analysis of the prominent drivers, opportunities, and trends expected to shape future expansion outlook. The report provides a comprehensive assessment of the prominent segments and geographies which are likely to benefit market players in the forthcoming years.

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in the US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have in our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analysed.

Research Insight: https://www.factmr.com/report/4732/medical-mask-market

Content Source: https://www.factmr.com/media-release/1485/global-medical-mask-market

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States

Untitled 1 1024x538 1 captis executive search management consulting leadership board services

Proximie Raises $38m Series B Funding To Accelerate Its Expansion in U.S. and European Markets

Untitled 1 1024x538 1 captis executive search management consulting leadership board services

Proximie is a health technology platform company focused on digitizing operating and diagnostic rooms.

Today the company announced the completion of its $38 million Series B equity financing. The round was led by F-Prime Capital, with participation from new investors Questa Capital, Eight Roads, Maverick Ventures, and the support of existing investors Global Ventures, BECO Capital, and Cedar Mundi Ventures.

The company’s mission is to save lives by sharing the world’s best clinical practices. The platform combines human expertise with the power of augmented reality (AR), machine learning (ML), artificial intelligence (AI), and advanced telecommunications.

Proximie will use the proceeds to accelerate its expansion in the U.S. and European markets. Significant investment will be directed toward commercial efforts, including new technology implementations, in addition to research and development.

The company was founded by Dr. Nadine Hachach-Haram FRCS (Plastics) – (B.E.M., British Empire Medal), in 2016. The company is building a network of operating rooms, where every interaction is captured, digitized, cataloged, and analyzed. By digitizing surgery, Proximie can accelerate the adoption of best practices and help to create better patient outcomes.

Proximie has enjoyed rapid growth over the last 12 months, having conducted over 10,000 surgical interactions in 300 hospitals in over 40 countries.

Untitled 1 1024x538 1 captis executive search management consulting leadership board services

RhoVac Reports to Mount Sinai Hospital in New York Join Phase IIb Study in Prostate Cancer

Untitled 1 1024x538 1 captis executive search management consulting leadership board services

RhoVac AB, a Swedish cancer immunotherapy company, announces today, April 21st 2021, that the prestigious Mount Sinai hospital in New York is initiated today as the latest addition to US trial centres in RhoVac’s clinical phase IIb study, “BRaVac”, in prostate cancer.

Mount Sinai Hospital, founded in 1852, is one of the oldest and largest teaching hospitals in the United States, and it is widely recognised and one of the leading hospitals in the US, and indeed in the world, and as such RhoVac is extremely proud to declare its participation in the BRaVac trial.

The participation of Mount Sinai was directly caused by the FDA approval of RhoVac’s Fast Track Designation. Immediately after the news on the Fast Track Designation was made public, Mount Sinai contacted RhoVac via its Scientific Advisory Board member, Professor Per-Anders Abrahamsson, who brokered the connection to RhoVac management. It is an honour for RhoVac, and a recognition of the potential of its drug candidate, that such a world leading hospital spontaneously seeks to join its clinical trial.

The site initiation visit is held, today, April 21st , and the study will be supervised at Mount Sinai by Professor Ash Tewari. In the trial, RhoVac’s drug candidate, RV001, will be used in prostate cancer patients that have previously had a prostatectomy or definitive radiation therapy, but that now have suffered a “Biochemical Recurrence” (rising PSA) but who still have not developed detectable metastases. The objective of the development of RV001 is to prevent/delay the recurrence of cancer and its progression to a metastatic state. If a clinical proof of concept is obtained in prostate cancer, several other cancer indications would also be candidates for development.

RhoVac CEO, Anders Månsson, comments: “I was of course delighted when I learned that Mount Sinai wanted to join our study. I regard this as yet another example of the recognition that the Fast Track Designation has brought us already, and I am happy that we could get started so quickly. I wish Mount Sinai welcome on board the trial team, and I look forward to our collaboration”.

fb image 3912 captis executive search management consulting leadership board services

UCI Urology Team Developing Unique Endoscope to Improve Kidney Stone Surgery

UCI Urology (four Urologists), who specialize in kidney stone diseases include Dr. Pengbo Jiang, Dr. Jaime Landman, Dr. Roshan Patel, and Dr. Ralph V. Clayman, have teamed up with UCI CALIT2 engineers, Dr. William Mao, Dr. Mike Klopfer, and G. P. Li to design a new ureteroscope that is capable of removing all kidney stone fragments during surgery.

The team has six months to complete the project and has received a grant to develop the technology.

UCI Urology, Team Developing Unique Endoscope to Improve Kidney Stone Surgery
UCI Urology Team Developing Unique Endoscope to Improve Kidney Stone Surgery

Approximately 10% of the U.S. population will experience a kidney stone. The primary treatment goals are to remove the stone with the least amount of patient discomfort and to prevent recurrence. One of the least invasive options for surgery involves using a non-incisional approach by entering the urinary tract with a ureteroscope. This type of endoscopic approach allows the urologist to access a stone and use a laser to break the stone into fragments.

Unfortunately, with the current technology, many of the smallest fragments cannot be recovered and removed. In fact, with the ureteroscope, even the best stone clearance rates are no better than 50 to 60%. The remaining fragments (about 2mm or smaller in size) can contribute to the formation of recurring stones within two years in as many as 40% of patients.

The UCI team seeks to develop instrumentation that is able to leave the kidney fragment-free following stone removal. The team’s proposal has been awarded a UCI Beall Applied Innovation Proof of Product (POP) grant, a funding program that accelerates commercially promising technology.

Dr. Ralph Clayman stated, “The POP grant has empowered and energized our work in this area. I am optimistic that given the great partnership we have with CALIT2 and the School of Engineering, within six months we will have a working prototype. This work has the potential to vastly improve surgical outcomes for all patients with kidney stones.”

The team has six months to complete this project and will utilize the Surgical Education and Research Center located at UCI Medical Center, Orange, CA. If successful, a disposable ureteroscope will be created that is able to remove all stone fragments, regardless of size. The ureteroscope will have additional features designed to improve the efficiency and effectiveness of stone removal, such as multiple laser channels and multidirectional deflection.

UCI Urology is at the forefront of research, providing patients with the best in innovative and less invasive urologic care. The department has a core mission to discover new advances in healthcare, teach tomorrow’s medical professionals, and heal patients with individualized care.

Untitled 1 1024x538 1 captis executive search management consulting leadership board services

FemTech Leader Willow ® Adds Diverse Set Of Investors In Extended Series C Round

Untitled 1 1024x538 1 captis executive search management consulting leadership board services

Willow, the company forever changing the way moms pump with the world’s first all-in-one, in-bra wearable breast pump with full spill-proof mobility, today announced an additional $26.8 Million in funding through a Series C Extension round –  led by Endeavour Vision, alongside NEA (New Enterprise Associates), Pura Vida Investments, Purple Arch Ventures (a part of Alumni Ventures Group), Logos Capital, and Gaingels.

This extension brings Willow’s total Series C investment to $81.8 Million.  With the most innovative breast pump on the market, Willow will use its latest growth capital funding to invest in new products and further expand its reach.

“We are excited to lead Willow’s Series C extension to further support the accelerated growth ahead for the company,” said Rob Barmann, Partner at Endeavour Vision. “As the innovation leader in its category, we believe that Willow will continue to develop groundbreaking innovations that disrupt the FemTech and MedTech industries.”

Recognizing that the functionality of breast pumps hadn’t changed in decades, Willow became a pioneer in the FemTech category by reinventing the breast pump. Willow’s proprietary, patented technology offers 100% spill-proof mobility for pumping moms, giving them freedom, dignity, and enabling joy in an otherwise stress-inducing aspect of motherhood.

“I’m excited about the growth we’ve been able to accomplish, and impact we’ve had, in such a short time, towards our mission of bringing joy to motherhood,” said Willow CEO, Laura Chambers. “With this additional funding, we will expand our international presence, grow brand awareness, and accelerate our innovative R&D pipeline of products that solve real problems for moms.”

Willow launched as a direct-to-consumer brand, bringing life-changing technology to women experiencing new motherhood.  Willow has since expanded to reach moms through retail and insurance channels, and was the fastest-growing brand in 2020 in retail for breastfeeding systems, according to NPD Group.  Its innovative breast pump has impacted more than 130,000 moms and counting.

Untitled 1 1024x538 1 captis executive search management consulting leadership board services

Medtronic Receives U.S. FDA Approval for Pipeline™ Flex Embolization Device with Shield Technology™

Untitled 1 1024x538 1 captis executive search management consulting leadership board services

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received approval from the United States Food and Drug Administration (FDA) for Pipeline™ Flex Embolization Device with Shield Technology™.

Medtronic developed Shield Technology, a proprietary breakthrough in biomaterial science, to advance flow diversion therapy by introducing the first surface-modified implant device which demonstrates reduction in material thrombogenicity, a reduction in the tendency of the surface treatment material to create clots. NYU Langone Health in New York City performed the first patient procedure in the nation with the new device.

Celebrating its 10-year anniversary in the U.S. in 2021, Pipeline Flex Embolization Device diverts blood flow away from a brain aneurysm. The first commercially available flow diverter in the market, the device features a braided cylindrical mesh tube that is implanted across the base, or neck, of the aneurysm. The device interrupts blood flow into the aneurysm, reconstructing the diseased section of the parent vessel. Pre-clinical testing shows how Shield Technology improves Pipeline Flex by reducing the thrombogenicity of the device material.

“The Pipeline Flex-Shield that we used today at NYU Langone to treat a giant left internal carotid aneurysm, represents a pivotal milestone in the evolution of flow diversion therapy—establishing a new vanguard for safe and effective management of complex cerebral aneurysms,” said Peter Kim Nelson, M.D., chief of Interventional Neuroradiology and professor of Radiology and Neurosurgery at NYU Langone Health. “Our team has long-anticipated the availability of this device for patients in the United States. The surface modification of the implant has demonstrated reduced material thrombogenicity,  discernably aiding delivery through tortuous vascular anatomy with improved delivery and resheathing forces compared to earlier generation flow diverters.”

Published on June 1, 2020, in the Journal of NeuroInterventional Surgery (JNIS), results from the SHIELD Study (Periprocedural to 1-year safety and efficacy outcomes with the Pipeline Embolization Device with Shield technology for intracranial aneurysms: a prospective, post-market, multi-center study) demonstrate that the third-generation Pipeline Flex Embolization Device with Shield Technology continues the strong record of safety and efficacy of flow diversion therapy with the Medtronic family of products. Results show 77.2% complete aneurysm occlusion at 12 months, a 3.2% primary safety endpoint, and 93.1% complete wall apposition post-procedure.

“In addition to addressing material thrombogenicity, Shield Technology improves device performance  by reducing the force required for both delivery and resheathing of the device. We believe that Shield Technology opens up a new range of options for physicians to continue to achieve improved patient outcomes,” said Dan Volz, president of the Neurovascular business, which is part of the Neuroscience Portfolio at Medtronic. “Ten years ago, Medtronic changed the treatment paradigm in brain aneurysms with the approval of Pipeline Embolization Device, and we continue to challenge ourselves to deliver solutions that improve outcomes and increase value for all healthcare stakeholders.”

An estimated 500,000 people throughout the world die each year due to ruptured brain aneurysms, with half the victims younger than 50 years of age. As the most studied flow diverter worldwide, Pipeline Embolization Device has been used to treat patients in the United States since 2011 and is now available with Shield Technology.

“Brain aneurysms are much more common than most people believe and require early detection, accurate diagnosis, and prompt treatment to maximize the chances of survival,” said Todd Crawford, founder, Lisa Foundation, dedicated to his wife Lisa who lost her life to complications from a brain aneurysm. “As a valued partner who shared our mission, we commend Medtronic for its continued commitment to pioneering new therapies and approaches to treating brain aneurysms that improve patient outcomes and saves lives.”

Untitled 1 1024x538 1 captis executive search management consulting leadership board services

Vesalius Cardiovascular Reaches a New and Advanced Pre-Clinical Milestone

Untitled 1 1024x538 1 captis executive search management consulting leadership board services

Vesalius Cardiovascular Inc. (VCI), a Canadian MedTech company developing a Transfemoral Mitral Valve Repair (TMVr) solution, announced today the achievement of a new pre-clinical milestone with its 180-day chronic animal study.

Vesalius Cardiovascular notes the predetermined endpoints of the study were the feasibility and durability of VCI’s papillary muscle anchoring device. Both endpoints were confirmed at the 180-day mark.

Dr. Peter Skarsgard, veteran cardiac surgeon and VCI’s Chief Scientific Officer, commented, “Our catheter-based solution can reproduce surgical mitral valve repair, but without the burden of the operation. We designed and developed a TMVr solution that is based upon proven surgical principles and material. Our concept is derived from the clinically proven chordal replacement technique and uses a papillary muscle anchoring device. In this specific study, our anchors replaced the native chordae attachments to the papillary muscles and are successfully carrying the load of the functioning anterior leaflet, preventing mitral regurgitation. This is proof that our anchoring device can durably reproduce a surgically placed suture in the papillary muscle.”

Echocardiographic images were obtained during the procedure and, subsequently, at seven, 30 and 180 days by Dr. Christopher Durkin, a cardiovascular anaesthesiologist, echocardiographer, and VCI’s clinical advisor, who added, “Imaging at 180 days confirms the absence of mitral regurgitation and, more importantly, the absence of anchor migration, proving that VCI’s anchors are acting exactly like the native chordae attachments.”

“This milestone is a major step in our development plan,” added Vincent Ledoux, VCI’s Chief Operating Officer. “Despite the pandemic, we were able to maintain our timeline intact thanks to the firepower of eight experienced biomedical engineers, continuously translating decades of cardiovascular expertise into a TMVr solution. We have transformed a complex operation (open heart) that uses a simple repair tool (sutures) into a sophisticated device with a simple delivery procedure.”

Dr. Jacqueline Saw, structural interventional cardiologist and VCI’s clinical advisor, noted, “The VCI solution is comprehensive mitral valve repair, delivered with a catheter. The device design leads to remarkable simplification and standardization of the delivery procedure, from case to case, with no compromise on effectiveness. This optimizes user needs, for both patient and provider.”

“Our unique solution is monopolistic in that we can treat the full spectrum of Degenerative Mitral Regurgitation, whether simple or complex, with or without annular dilation, using adapted chordal replacement and annuloplasty concepts in one device. No other solution can offer that,” said Dr. Skarsgard, adding, “Simply said, in any size valve, our device can treat any expression of degenerative disease – it is a one-size-fits-all solution.”

To date, VCI has raised $5 million from a solid base of investors and early believers and is expecting to reach the First-In-Human stage by mid-2022.

Untitled 1 1024x538 1 captis executive search management consulting leadership board services

IN.PACT AV Drug-Coated Balloon Is First and Only to Show Superior and Sustained Results Through Two Years Compared to PTA in Treating Arteriovenous Fistulae Lesions

Untitled 1 1024x538 1 captis executive search management consulting leadership board services

April 20, 2021

IN.PACT AV Drug-Coated Balloon: Medtronic announced the safety and effectiveness results through 24 months for the IN.PACT AV Access clinical study.

The data, which were presented virtually as a podium first at the 2021 Charing Cross Symposium, demonstrated that the IN.PACT™ AV drug-coated balloon (DCB) is the first and only DCB to show sustained and superior effectiveness through two years compared to standard percutaneous transluminal angioplasty (PTA) in end-stage renal disease (ESRD) patients with de novo or non-stented restenotic native arteriovenous fistulae (AVF) in the upper extremity.

“A patient who receives hemodialysis will often need to have several reinterventions each year to maintain patency and keep critical access sites open and functioning properly,” said Andrew Holden, MBChB, FRANZCR, director of interventional radiology at Auckland Hospital and associate professor of radiology at Auckland University. “Being able to show these results at two years will ultimately impact standard of care for patients undergoing dialysis. For my patients, these durable results translate into fewer reinterventions and a better quality of life.”

AV fistulae are created and used to deliver hemodialysis to patients with ESRD. Over time, vessel restenosis limits the ability to use AV fistulae effectively. In order to restore function, patients often undergo one to three AV fistula maintenance procedures per year.3 The need for frequent reinterventions can result in significant disruptions to critical hemodialysis care and increased costs to the healthcare system. Drug-coated balloons have the potential to extend the time between reinterventions by maintaining AV access site patency, therefore maximizing a patient’s uninterrupted access to lifesaving dialysis care.

Over two years, the IN.PACT AV DCB group demonstrated a continued clinical benefit compared to the PTA control group. Key data highlights per Kaplan-Meier estimates for this dataset include:

  • Target lesion primary patency through 24 months was 52.2% in the IN.PACT AV DCB group compared to 36.2% in the PTA control group (log-rank p<0.001).
  • Access circuit primary patency through 24 months was 39.5% in the IN.PACT AV DCB group compared to 25.4% in the PTA control group (log-rank p<0.001).
  • Freedom from all-cause mortality through 24 months was 82.4% in the IN.PACT AV DCB study group and 82.8% in the PTA control group (log-rank p=0.829).

“Medtronic is committed to providing physicians and patients with technology to improve dialysis access maintenance outcomes and reduce disruptions to care. Both our investment in this study as well as its results are a clear testament to this,” said Dave Moeller, president of the Peripheral Vascular Health business, which is part of the Cardiovascular Portfolio at Medtronic. “These results are significant not only because IN.PACT AV is the only DCB to meet both safety and effectiveness endpoints through six months, but also because it demonstrates that at two years, IN.PACT AV does better than PTA in helping to keep critical lifelines open and reduce the number of times a patient needs to return to their physician for a reintervention.”


The IN.PACT AV Access study is a prospective, global, single-blinded, randomized controlled trial (RCT), which enrolled 330 subjects at 29 sites in the United States, Japan and New Zealand. Results of the six-month pivotal IN.PACT AV Access study were presented at CIRSE in September 2019 and also published in The New England Journal of Medicine in August 2020.

Untitled 1 1024x538 1 captis executive search management consulting leadership board services

Martell Diagnostic Laboratories Announces HERTEST: Groundbreaking Way to Detect Effectiveness of Breast Cancer RX Globally

Untitled 1 1024x538 1 captis executive search management consulting leadership board services

April 20, 2021

Martell Diagnostic Laboratories, Inc. has announced the launch of its new diagnostic test for breast cancer patients – HERTEST.

HERTEST is a blood test that looks for a protein called human epidermal growth factor receptor (HER2), which is shed into the blood stream of patients with growing breast cancer tumors. HERTEST uses state-of-the-art antibodies to detect HER2 at diagnosis, as well as uncovering HER2 tumors in women with primary tumors originally testing negative at diagnosis. HERTEST is available both as a  traditional lab test and as a lateral flow assay. The traditional lab test is available in the United States and the lateral flow assay will be made available for use in developing countries where lab testing is not available.

“We’re tremendously excited to give women and their oncologists all over the world a better way to guide cancer therapy,” said Michelle Edwards, CEO of Martell Diagnostics Laboratories. “HERTEST can help deliver on the promise of targeted therapy for millions of women.”

Michelle Edwards, new CEO of Martell Diagnostic Laboratories, leads the Minnesota-based team with a primary goal of offering their flagship test, HERTEST, to the masses for improved onco-therapeutics and drug efficacy for breast cancer patients that will reduce costs and drug-use. HERTEST is currently in clinical trials and partnership with the University of Minnesota, Mayo Clinic, and Kilimanjaro Cancer Center in Tanzania, with planned expansion to Bangladesh and Honduras.

In the U.S., 300,000 women are diagnosed with breast cancer each year with HER2 breast cancer making up about 20% of those cases. Globally, over 2.3 million new breast cancer diagnoses are delivered annually, with even higher rates of HER2 positivity.  HERTEST will help answer breast cancer patients’ questions and give physicians specific, real time data regarding patient status and better treatment options.

Targeted therapy in breast cancer treatments traditionally requires hefty costs and limitations leading oncologists to seek new tests that will lower drug use and increase quality of life. Currently, women wait 10-14 days to receive results about the progression of their condition, losing valuable time in treatment. With more than 100 peer-reviewed articles supporting the importance of HER2 testing for treatment, HERTEST monitoring provides useful information to support cancer treatment de-escalation within two days of the test.

Untitled 1 1024x538 1 captis executive search management consulting leadership board services

ESPRIT CAM Improves Productivity for Long Part Machining by Automating Multi-spindle Program Creation

Untitled 1 1024x538 1 captis executive search management consulting leadership board services

April 20, 2021

ESPRIT CAM: New computer-aided-manufacturing (CAM) technology has been introduced by ESPRIT CAM, part of Hexagon’s Manufacturing Intelligence division that provides manufacturers with the control and flexibility needed to use multi-spindle and multi-channel computer-numerical-control (CNC) machinery for the machining of long parts.

More accurate simulation of spindle transfers and bar pulls enables manufacturers to exploit multi-tasking machinery with high productivity program creation of error-free toolpaths.

Machining long parts, such as shafts and axles, is challenging because they require that the workpiece is supported throughout to maintain cutting speed and surface quality. The main and sub spindles must be synchronised to ensure that cutting can be performed while both spindles hold the workpiece for maximum support.

Bars are also frequently repositioned in incremental steps to keep workpieces rigid, as well as to account for limited bed length. Because the repeat repositioning of the bar presents a collision risk, it benefits machinists if they are supplied with NC code that tracks machine motion for greater flexibility and readability at the machine control.

Without the ability to track machine motion, a significant amount of time is spent hand-editing NC code and troubleshooting programs before production begins using complex multi-tasking scenarios. ESPRIT TNG CAM software now automatically tracks the location of work offsets regardless of part position by enabling programmers to define the offset and offset translations, or the points at which offset changes occur.

In addition to enabling precise simulation, this eliminates the need for custom settings or calculations to the machine post to ensure that parts are machined accurately and makes it possible to program a greater number of complex machining scenarios without error.

“ESPRIT TNG is ‘the next generation’ CAM because it provides an exact digital replica of every facet of the machining environment to help manufacturers use the world’s most sophisticated, cutting-edge machine tools with confidence,” said Olivier Thenoz, ESPRIT principal product manager. “The ability to accurately track parts throughout complex operations means that users can make the most of the combined power of software and machinery for advanced multi-tasking, and that they have the freedom and flexibility needed to machine exactly the way they want to.”

ESPRIT TNG now also enables manufacturers to perform face-milling operations with a unique “roll-in” lead-in strategy recommended by Sandvik Coromant to improve surface quality, reduce cycle time, and extend tool life. This lead-in technique positions the cutter for ideal thick-to-thin chip formation, which indicates that the insert engages the material deeply enough at entry to make a significant cut before exiting smoothly to reduce vibration and ensure consistent, high-quality surface finish.

In addition to being less damaging to cutter inserts, this strategy eliminates the need to manually calculate face-milling stepovers during the programming process, which automatically ensures a consistent and even surface across the entire workpiece.

The new release also offers productivity benefits for 3-axis operations. Toolpath creation is now 20 times faster, meaning that toolpath that once took 30 minutes to generate can now be calculated in about two minutes. Furthermore, a new 3-axis toolpath can now be created in ESPRIT TNG from an existing operation without recalculating the entire toolpath. Areas in collision can be trimmed from toolpath generated for use with short cutting tools, or re-machining operations can be created with a long tool to cut only areas that cannot be reached with the shorter tool.

ESPRIT TNG 4.7 is available from ESPRIT CAM now